# Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

> **NCT04617002** · — · APPROVED_FOR_MARKETING · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Glioma
- H3 K27M

## Interventions

- **DRUG:** ONC201 (dordaviprone)

## Key facts

- **NCT ID:** NCT04617002
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617002, "Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04617002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*